ERIS Lifesciences Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹757Cr
- +7.4% YoY
- −6.2% QoQ
- Net profit
- ₹279Cr
- +173.5% YoY
- +156% QoQ
- Margin
- 36%
- 0 pp YoY
- +1 pp QoQ
Guidance rank: #50 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
1 of 3 strong
The short version
International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm). Eris Lifesciences expects DBF revenue growth at 1.3x of covered market growth in FY27 with DBF EBITDA margin steady at ~37%, and higher margin in H2 than H1.
From ERIS Lifesciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm).
- EU CDMO: No base case revenue expected in FY27; any revenue would be upside; major revenues anticipated from FY28 onwards.
- Domestic Formulations (DBF): Overall DBF growth around 11-12%; insulin and derma therapies already outperforming; cardiovascular (CVD) segment catching up; other oral anti-diabetic (OAD) therapies expected to require more time to catch up.
2 more points from ERIS Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what ERIS Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR 160-180 crores invested in developing a large biotech play (DS facility).
- INR 250 crores invested in Bhopal fill and finish site, which is expected to improve margins and open new markets once operational.
- A map facility set up at Bhopal, considered future-focused but delayed by 1 to 1.5 years.
- Additional plant investment for Swiss Parenterals with commissioning expected in April, doubling current parenteral capacity.
- No major CapEx planned for remediation related to EU GMP inspection; mainly procedural and training-related improvements.
2 more points from ERIS Lifesciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what ERIS Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from ERIS Lifesciences Ltd's call on order book
Create a free account to keep reading this call
ERIS Lifesciences Ltd — Quarterly revenue & net profit
ERIS Lifesciences Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 757 | 705 | +7.4% | 807 | -6.2% |
| Operating profit (EBITDA) | 272 | 252 | +7.9% | 282 | -3.5% |
| Operating margin | 36% | 36% | 0 pp | 35% | +1 pp |
| Profit before tax | 159 | 129 | +23.3% | 145 | +9.7% |
| Net profit (PAT) | 279 | 102 | +173.5% | 109 | +156% |
| EPS (₹) | 20.33 | 6.89 | +195.1% | 7.32 | +177.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹892 Cr, net profit ₹187 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What ERIS Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
ERIS Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were ERIS Lifesciences Ltd Q4 FY26 results?
International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm). Eris Lifesciences expects DBF revenue growth at 1.3x of covered market growth in FY27 with DBF EBITDA margin steady at ~37%, and higher margin in H2 than H1.
What is ERIS Lifesciences Ltd share price analysis?
ERIS Lifesciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.1 with a market cap of ₹19,057 Cr. Investors should review the full earnings analysis for detailed insights.
Is ERIS Lifesciences Ltd planning capital expenditure?
INR 160-180 crores invested in developing a large biotech play (DS facility).
Keep ERIS Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
